STAT+: Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows
Amid debate over potential abuse of the U.S. patent system by the pharmaceutical industry, moves…
Category: drug pricing
STAT+: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds…
STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
And so, another working week will soon draw to a close. Not a moment too…
The little-known bill that made drugs more affordable
This is Part 4 of “Behind the Counter,” an in-depth video series demystifying the complex…
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug…
STAT+: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals
A U.S. government agency said that a planned move by Johnson & Johnson to alter…
STAT+: Takeaways from the DNC on the health care fights ahead
WASHINGTON — The Democrats were not subtle this week about what their health care priorities are…
Abortion rights and drug pricing program take spotlight at first night of DNC
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Democratic platform favors slate of smaller goals over a health overhaul
WASHINGTON — Gone are the days when Democrats bickered over wholesale reform of the American…
Harris pledges to scrap billions in medical debt with new presidential platform
WASHINGTON — Vice President Harris says she wants to cancel billions of dollars in medical…
‘Zoobiquity’: How animals have figured out disease better than humans
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: What do Biden’s drug price comparisons reveal? Not much
WASHINGTON — The White House is touting just how much its new Medicare negotiation process…
New Medicare drug prices, antimicrobial-resistant meningitis, unlucky American women
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
Medicare drug price negotiation didn’t benefit Biden — but it may help Harris
WASHINGTON — When Vice President Kamala Harris takes the stage at the Democratic National Convention…
STAT+: Medicare announces drug prices for historic first round of negotiations
WASHINGTON — The day drug makers dreaded has finally arrived. Medicare officials on Thursday unveiled…
STAT+: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B
A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably…
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
Trump’s real health care agenda isn’t in Project 2025 — it’s in his own words
WASHINGTON — Former President Trump has made it abundantly clear that nobody else speaks for…
STAT+: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England
LONDON — Patients in England with a rare blood disorder will now be able to…
Opinion: Give pharmaceutical execs the benefit of doubt — but they need to work for it
The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical…
Opinion: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight…
STAT+: Express Scripts overcharged postal workers by $45 million, audit says
Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal…
Harris health care agenda swiftly hailed by progressives and reproductive rights groups
WASHINGTON — President Biden’s announcement Sunday that he would be dropping out of the presidential…
Opinion: Readers respond to essays on philanthropy and nursing schools, opioid overdoses, and more
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the…
STAT+: Here come Medicare’s first negotiated drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Medicare drug pricing rules will delay access to promising therapies
Medicare’s new guidelines cover how it will conduct the drug price negotiations authorized by the…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FTC report finds PBMs profit at the expense of patients and independent pharmacies
In stark terms, the Federal Trade Commission found in a report released Tuesday that pharmacy…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Judge rules against Boehringer Ingelheim in pharma’s latest legal loss on Medicare negotiation
WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biden and Trump spar over Medicare and abortion in a presidential debate filled with mistakes and falsehoods
WASHINGTON — For the most part, substantive debates on health policy between President Biden and…
Key health care topics to watch out for at the Biden-Trump debate
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Exclusive: European VC Forbion hires Dyne CEO, expands into US
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Intellia says its CRISPR-based therapy can be redosed
Want to stay on top of the science and politics driving biotech today? Sign up to get…
One firm, two conflicting takes on Alnylam’s HELIOS-B
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The findings from Alnylam’s highly anticipated readout
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more
And so, another working week will soon draw to a close. Not a moment too…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A biotech’s binary bet ends badly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA offers new guidelines for Covid-19 vaccine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novo Nordisk CEO agrees to Bernie Sanders’ demand to testify on Ozempic, Wegovy prices
WASHINGTON — Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate after Sen….
STAT+: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more
And so, another working week will soon draw to a close. Not a moment too…